Remogliflozin Etabonate: First Global Approval.
Remogliflozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor, which is to be administered as remogliflozin etabonate (Remo, Remozen), the prodrug for remogliflozin, recently received its first approval as a treatment for type 2 dia.....